Advertisement

The Scientist

» clinical trials and microbiology

Most Recent

image: Are the Kids Alright?

Are the Kids Alright?

By | March 1, 2012

Two key pieces of legislation, enacted to spur drugmakers into testing pharmaceutical products in children, are up for reauthorization in the US Congress this October. Have they done their jobs?

6 Comments

image: Suspected Effects of Vitamin D

Suspected Effects of Vitamin D

By | March 1, 2012

Vitamin D has a variety of actions in the body. It binds to the vitamin D receptor (VDR), which then binds to the retinoid X receptor (RXR) and activates the expression of numerous genes. 

0 Comments

image: Tricky Trials

Tricky Trials

By | March 1, 2012

Studies on safety, efficacy, or dosing of drugs in children, or on nutritional supplements, are not run-of-the-mill.

0 Comments

image: Biota Babble

Biota Babble

By | March 1, 2012

Editor's choice in immunology

2 Comments

image: Vitamin D on Trial

Vitamin D on Trial

By | March 1, 2012

Prevention trials for vitamins and supplements are notoriously difficult, but some researchers aren’t giving up on finding proof that vitamin D helps ward off disease.

52 Comments

image: Alzheimer's Drugs Harmful?

Alzheimer's Drugs Harmful?

By | February 20, 2012

The researcher who helped develop an Alzheimer's treatment now in clinical trials warns that the compound may actually impair memory.

2 Comments

image: TB Screen Glows Green

TB Screen Glows Green

By | February 13, 2012

Infection by GFP-encoding viruses enables quick, easy detection of tuberculosis in patient samples.

2 Comments

image: FDA's Biosimilars Guidance

FDA's Biosimilars Guidance

By | February 13, 2012

The federal agency finally breaks out some information on what it might take to get generic biological drugs approved.

3 Comments

image: <em>C. diff</em> Infection Source Unclear

C. diff Infection Source Unclear

By | February 7, 2012

Only a quarter of Clostridium difficile infections in one hospital system were traced to contact with a symptomatic patient.

15 Comments

image: Federal Biosecurity Panel Speaks

Federal Biosecurity Panel Speaks

By | February 1, 2012

The US National Science Advisory Board for Biosecurity explains why it recommended redacting the details of studies reporting on a highly transmissible H5N1 strain.

6 Comments

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
CEM
CEM
Advertisement
The Scientist
The Scientist
Life Technologies